


Getting investigational medicinal products to the patient: **three routes**

Reliable supply of investigational medicinal products (IMPs) is key to ensuring patients are dosed on time and clinical trials run efficiently.

In clinical trials, IMPs are traditionally shipped from suppliers to clinical centers and administered by investigators, or collected from the site and taken home. Decentralized and hybrid models, which are fast becoming the preferred approach from patients and sponsors, are changing this dynamic as they bring a new alternative to the common routes for getting IMPs to patients.

Here are three routes for getting IMPs to patients to support a successful trial:



Did you know?

Over 1,300 trials with a decentralized and/or virtual component initiated in 2022. A 28% increase from 2021, and 93% from 2020.¹

Moving some trial site activities into patients' homes can increase recruitment by over 60% and typically maintains patient retention at over 95%.²

78% of patients would find it helpful if IMPs were delivered to their home.³

World Courier has unique global capabilities and specialists prepared for your tomorrow.

From clinical trials to patient homes, we manage the complexities that bring your biopharmaceutical innovations to those that need it most.

Find out how we manage the complex with care